CRR_Call Tracker

Text/HTML

Text/HTML

ValueProductView

ValueProductPastPerformance

Company NameReco DateReco PriceExit PriceExit Date% ReturnIn days
ITC Ltd. 28/12/2023464.20487.5002/01/2025 5.02% 1 yrs
Britannia Industries Ltd. 27/07/20234,875.805,028.2512/11/2024 3.13% 1 yrs
JSW Steel Ltd. 22/02/2024826.951,003.0026/09/2024 21.29% 217 days
Bajaj Auto Ltd. 22/08/20249,910.0011,930.0017/09/2024 20.38% 26 days
Dr. Reddy's Laboratories Ltd. 26/10/20235,429.306,536.0005/07/2024 20.38% 253 days
Shriram Finance Ltd. 25/04/20242,430.102,955.0028/06/2024 21.60% 64 days
Coal India Ltd. 25/01/2024389.50501.6022/05/2024 28.78% 118 days
Infosys Ltd. 27/10/20221,522.601,411.6019/04/2024 -7.29% 1 yrs
State Bank Of India 25/05/2023581.30782.0505/03/2024 34.53% 285 days
The Indian Hotels Company Ltd. 24/08/2023401.85517.9007/02/2024 28.88% 167 days

CRR_MVC_PastPerformance

Text/HTML

Our Other Trader Products

EasyDNNNews

Karan Dsij
/ Categories: Pre Morning

Index trend and stocks in action October 22, 2018

In the final trading session of the week, the NSE benchmark Nifty opened the session with a gap-down and drifted lower as the day progressed. However, a small recovery was seen from the lows of the day, but the index registered a loss of 1.43 per cent and ended the day at 10,304. The price action formed a small body negative candle with a downside gap. Going ahead, the level of 10,250 is a crucial support level as it is near about 78.6 per cent retracement level of the recent pullback rally. Failure to hold this support level would lead to further downside, where the index most probably will test the recent lows of 10,140-10,200. On the upside, the gap area which has been created on the October 19, 2018, is likely to act as a resistance zone (10,380-10,436). 

Biocon: The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Ogivri, a biosimilar to Roche's Herceptin (trastuzumab). 
  
Lupin: Lupin Neurosciences, the specialty pharma division of Lupin, has announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion recommending the marketing authorisation of NaMuscla (mexiletine hydrochloride) for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders. 
  
Piramal Enterprises: Piramal Enterprises has refuted rumours of any sort that have been floating around with respect to its real estate loan portfolio companies. The rumours relate to loan defaults to PEL/Piramal Capital & Housing Finance Limited (PCHFL) by real estate developers such as Lodha, Omkar. Vatika, Embassy, Radius, Nahar, Aristo, Supertech, etc. 
  
Reliance Power: Sasan Power, the 100 per cent subsidiary of Reliance Power, has bagged an arbitration award against North American Coal Corporation (NACC). Subsequently, Sasan Power is required to pay only Rs 17 crore towards outstanding invoices as against NACC’s claims of Rs 235 crore. 
    
Tata Steel: A wholly-owned indirect subsidiary of the company, viz, TS Global Minerals Holdings Pte Ltd, has entered into an agreement to divest its entire stake in its wholly-owned step down subsidiary Black Ginger 461 Pty Ltd, which in turn holds 64 per cent in Sedibeng Iron ore Pty Ltd, South Africa, which is the operating company. The stake has been divested to IMR Asia Holding Pte Ltd, which is a group company of IMR Metallurgical Resources AG, a global metals and mining group headquartered in Switzerland, and a leading supplier of raw materials to the steel industry. 
  
Jet Airways: The company has clarified that the reports of talks with Tata are speculative. 

Previous Article Markets likely to see muted start tracking cues from Asian peers
Next Article Tejas Networks wins Rs. 111 crore naval order from Sterlite Tech
Print
1014 Rate this article:
5.0
Please login or register to post comments.

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR